Back to Search
Start Over
Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still's Disease.
- Source :
- European Journal of Rheumatology; Oct2022, Vol. 9 Issue 4, p217-220, 4p
- Publication Year :
- 2022
-
Abstract
- Macrophage activation syndrome is the most frequent life-threatening complication of adult-onset Still's disease. This is a nearly fatal case of a young patient, which has been refractory to corticosteroids, anakinra, tocilizumab, cyclosporine A, and etoposide, but eventually responded miraculously to salvage therapy with ruxolitinib. We review recent pertinent data related to the therapeutic value of ruxolitinib for macrophage activation syndrome triggered by adult-onset Still's disease. [ABSTRACT FROM AUTHOR]
- Subjects :
- STILL'S disease
MACROPHAGE activation syndrome
RUXOLITINIB
Subjects
Details
- Language :
- English
- ISSN :
- 21484279
- Volume :
- 9
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- European Journal of Rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 161540824
- Full Text :
- https://doi.org/10.5152/eurjrheum.2022.21064